Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Yarrow Bioscience, Inc.VYNE · Entity 6871 | Director | December 12, 2024 | December 13, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Yarrow Bioscience, Inc.
Report date December 12, 2024 · Filed December 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2034-12-11 | Direct | 20,000 |
Reported balance
After 2024-12-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-12-12 · Grant · Acquired 20,000 · Balance 20,000 F1: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2025, subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2025, subject to the Reporting Person's continuous service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 12, 2024 Filed Dec 13, 2024 21:15 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001415889-24-029291 · form4-12132024_041217.xml · derivative · entry 1 Borowski Christine · CIK 0002005073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-12-11 F1 · derivative.exercise_date: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2025, subject to the Reporting Person's continuous service through such date. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 22:07 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001209191-24-000456 · doc4.xml · derivative · entry 1 Borowski Christine · CIK 0002005073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-12-31 F1 · derivative.exercise_date: The option will vest and become exercisable as to 1/3rd of the shares subject to the option on each annual anniversary of the date of grant, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.